Akums reported a robust 12.4% year-on-year revenue growth in Q4 FY25, reaching Rs.1,073 crore. The company closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, showing a 7-basis point improvement. Akums secured a significant EUR200 million contract for pharmaceutical products in regulated European markets, expanding its global footprint. With investments in R&D and infrastructure, Akums is positioning itself for domestic and global pharmaceutical opportunities.
Despite flat year-on-year revenue due to industry challenges, Akums continues to focus on innovation, quality manufacturing, and global expansion. The company’s emphasis on complex formulations, novel delivery formats, and patient-centric innovations strengthens its position in the pharmaceutical landscape. With leadership’s commitment to long-term growth and creating value for stakeholders, Akums is poised for success in the global CDMO market.
Read more from theprint.in
